Search

everythinglearnresearchcommunity

for

Search:↓

A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

User shared progress on hair regrowth using 1.25 mg finasteride daily, 5% minoxidil, and a 1.5 mm dermaroller twice a week, with no side effects. Users discussed shedding phases, application methods, and the necessity of continuous treatment to maintain results.

Dutasteride reduces DHT more effectively in hair follicles than finasteride, but some individuals still experience hair loss despite treatment. Combining oral and topical finasteride may improve results, and some users experiment with topical dutasteride despite uncertainties about its absorption.

The user is treating hair loss with a regimen including Dutasteride, oral and topical Minoxidil, microneedling, and various supplements for overall health. They are considering adding tretinoin, stemoxydine/RU, DIM, Boron, and Fadogia Agretis to their routine.

A 24-year-old experienced improved hair growth using 5% minoxidil, 1 mg finasteride, and dermastamping, but faced side effects like low libido and mild erectile dysfunction. They plan to reduce finasteride dosage after full results and may consider a hair transplant if thinning recurs.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.

A 24-year-old male experienced an increase in estradiol levels and symptoms like gynecomastia and excessive sweating after using Minoxidil for hair loss. His estradiol levels decreased after he stopped using Minoxidil.

Isotretinoin may cause hair loss by increasing DHT through a precursor androgen, DHEAS. Treatments like topical antiandrogens (RU58841, pyrilutamide) and drugs increasing PPAR-y expression (pioglitazone) might prevent this hair loss.

A 28-year-old male shares progress on hair loss treatment using 0.5mg dutasteride and 5mg minoxidil, experiencing initial shedding but encouraged by community support. He also uses ketoconazole occasionally based on scalp oiliness.

Despite using Dutasteride, RU58841, and Minoxidil, hair loss continues due to low testosterone levels from taking 15mg of testosterone weekly, which may not produce enough estrogen. Increasing testosterone dosage and stabilizing hormone levels might help address the issue.

The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.

The user is exploring alternatives to finasteride and dutasteride due to concerns about side effects, and is using rosemary and jojoba oil, ketoconazole, minoxidil, microneedling, multi-peptide serum, saw palmetto, and stinging nettle for hair loss. They are also considering CB 03 01 and spironolactone.

A user experienced positive hair growth results using 5% topical minoxidil for a year and 1 mg finasteride for four months but is considering stopping finasteride due to persistent side effects like libido loss. Others in the conversation discuss similar experiences, suggest trying topical finasteride to reduce side effects, and emphasize the importance of overall health and lifestyle.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The user improved their hair loss from a Norwood scale 2.5/3 to 1.5/2 using treatments including 2.5 mg dutasteride, RU58841, 15 mg oral minoxidil, isoflavones, NAC, pumpkin seed oil, NAD+, and Vipelin, but still experiences temple recession. Other users expressed concern over the high dosages of oral minoxidil and dutasteride.

Alcohol-based minoxidil absorbs better but can cause irritation; non-alcohol-based is gentler. Topical dutasteride shows promise but needs more research; low-dose oral minoxidil (0.25 mg/day) is effective with fewer side effects. Ingredients like Procapil, Redensyl, caffeine, and Anagain in shampoos have limited evidence; ketoconazole shampoo can help when used 2-3 times a week with other treatments.

The conversation is about a user struggling with hair loss despite using dutasteride, finasteride, minoxidil, and dermaneedling. The user is considering other treatments but is hesitant to use RU-58841 due to side effects and is seeking advice on alternative solutions.

The user is experiencing positive results in hair regrowth using a regimen of 0.5 mg dutasteride, 5 mg oral minoxidil, ketoconazole shampoo, microneedling, and a combination of topical minoxidil with RU58841. They report no side effects and express gratitude for the support and inspiration from the community.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

A user is trying fluridil/topilutamide for hair loss and experiencing side effects like pain in the testicles and genital discomfort. They previously had adverse effects with finasteride, dutasteride, and RU58841, and are considering other treatments like topical dutasteride and spironolactone for maintenance before a hair transplant.

The conversation is about a person experiencing treatment-resistant androgenic alopecia despite using high doses of dutasteride and minoxidil, along with other treatments like microneedling and purilutamide. Suggestions include considering a hair transplant, checking medication authenticity, and exploring other treatments like RU58841 or topical estradiol.

The conversation discusses using a 0.03% topical Dutasteride solution for hair loss, as it may be more effective than Finasteride with fewer systemic side effects. OP plans to apply it daily for 100 days, then reduce frequency, due to past negative cognitive effects from oral treatments.

A user was prescribed a topical treatment for hair loss including Latanoprost, Minoxidil, Dutasteride, Hydrocortisone, and Progesterone, after using an oral Minoxidil and Finasteride combo without significant results. Concerns were raised about the long-term use of hydrocortisone, with suggestions to consult a doctor regularly.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.